eIF4E Inhibitors for Selective Cap-Dependent Translation Control

The patent applies local quality by designing small molecule inhibitors that specifically target the eIF4E/eIF4G protein-protein interaction interface. The compounds are engineered with specific molecular structures (containing heterocyclic rings, aromatic groups, and functional groups like carboxylates or sulfonates) that selectively bind to the hydrophobic groove of eIF4E, disrupting only the eIF4E/eIF4G interaction while leaving other translation machinery unaffected. This localized targeting achieves selective suppression of cap-dependent translation.

The small molecule inhibitors act as intermediary compounds that mediate the disruption of the eIF4E/eIF4G protein-protein interaction. These molecules serve as molecular mediators that bind to eIF4E and prevent eIF4G from binding, thereby indirectly suppressing cap-dependent translation initiation without directly interfering with ribosomal function or other translation elongation processes.

The patent applies segmentation by separating the translation initiation process into targetable components. By specifically targeting the eIF4E/eIF4G interaction - a discrete protein-protein interface - the inhibitors selectively disrupt cap-dependent translation of growth-promoting mRNAs while sparing IRES-dependent translation and other essential cellular processes. This segmentation allows differential inhibition of tumor cell translation without broadly affecting normal cell function.

The patent employs parameter changes by optimizing the molecular properties of the inhibitors, including their size (600 daltons or less), functional groups (carboxylates, sulfonates, phosphates), and binding affinity. These parameter optimizations ensure the compounds bind selectively to eIF4E with appropriate affinity, achieving sufficient inhibition of tumor cell growth while maintaining selectivity that spares normal cells at therapeutic doses.